Search clinical trials for: Respimat

Total 145 results

Fundacio Privada Mon Clinic Barcelona
GlaxoSmithKline

Recruiting

ANTES B+ Clinical Trial (ANTES B+)

Chronic Obstructive Pulmonary Disease

Spain
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Malignancy

China
Boehringer Ingelheim

Completed

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Pulmonary Disease, Chronic Obstructive

United States, Canada
Boehringer Ingelheim

Completed

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
Boehringer Ingelheim

Completed

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

China
Erasme University Hospital

Completed

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

Pulmonary Disease, Chronic Obstructive

Belgium
Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
Fraunhofer-Institute of Toxicology and Experimental...
Boehringer Ingelheim

Completed

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

Chronic Obstructive Pulmonary Disease

Germany
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Boehringer Ingelheim

Completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Pulmonary Disease, Chronic Obstructive

China
Università degli Studi di Ferrara

Terminated

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Italy
RWTH Aachen University

Withdrawn

Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD (CREATES)

COPD

Germany
Boehringer Ingelheim

Terminated

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Asthma

United States
Boehringer Ingelheim

Terminated

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Asthma

United States
Boehringer Ingelheim

Terminated

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Asthma

United States
Boehringer Ingelheim
HealthCore-NERI

Completed

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Pulmonary Disease, Chronic Obstructive

United States
University of Saskatchewan

Completed

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma

Asthma

Canada
Boehringer Ingelheim

Completed

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
University Hospital, Bordeaux

Completed

Description of the Ability to Learn How to Handle Inhaler Devices in COPD (INTUITIVE)

Chronic Obstructive Pulmonary Disease (COPD)

France
Boehringer Ingelheim

Completed

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Pulmonary Disease, Chronic Obstructive

United States, Germany
Boehringer Ingelheim

Completed

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Characteristics of Pts Initiating Spiriva Respimat in Asthma

Asthma

Germany
University of Saskatchewan

Completed

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Allergic Asthma

Canada
Boehringer Ingelheim

Completed

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Hungary, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan
National University of Malaysia

Completed

Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)

Chronic Obstructive Pulmonary Disease

Malaysia
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Chiesi Farmaceutici S.p.A.

Completed

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (TRIGGER)

Asthma

Argentina, Belarus, Bulgaria, Czechia, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine, United Kingdom
Şeyhmus KAPLAN

Completed

Hyaluronic Acid, Corticosteroid and Electrotherapy in Subacromial Impingement Syndrome

Subacromial Impingement | Pain, Shoulder
Boehringer Ingelheim

Completed

Re-usable Respimat® Soft MistTM Inhaler Study

Pulmonary Disease, Chronic Obstructive

Denmark, Netherlands, Finland, Belgium, Germany, Norway
Helsinki University Central Hospital

Completed

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Wheezing | Wheezy Bronchitis | Asthmatic Bronchitis | Obstruction Airway

Finland
Boehringer Ingelheim

Withdrawn

TARA Working Prototype [Version 2]: Feasibility Study

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Impact of Tiotropium Add-on Therapy in Patients With Asthma

Asthma

United States
Boehringer Ingelheim

Completed

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Pulmonary Disease, Chronic Obstructive

Israel, Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, Lithuania, Poland, Romania, Slovenia, Switzerland
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Asthma

United States
Lundquist Institute for Biomedical Innovation at...
Boehringer Ingelheim

Completed

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
University of Dundee
Boehringer Ingelheim; NHS Tayside

Completed

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol (INCOGNITO)

Chronic Obstructive Pulmonary Disease

United Kingdom
Boehringer Ingelheim

Completed

Greek NIS Spiolto ELLACTO

Pulmonary Disease, Chronic Obstructive

Greece
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Pulmonary Disease, Chronic Obstructive

Germany
Maastricht University Medical Center
AstraZeneca; Center for Integrated Rehabilitation and Organ Failure Horn

Unknown

The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours. (BOTH)

Chronic Obstructive Airway Disease

Netherlands
Boehringer Ingelheim

Completed

Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Specific Use-Result of Spiriva Respimat® in Asthmatics

Asthma

Japan
Imperial College London
Boehringer Ingelheim

Completed

Airway Effects of Tiotropium in Patients With COPD

COPD | LUNG DISEASES, OBSTRUCTIVE

United Kingdom
Verona Pharma plc

Completed

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

COPD

United States, United Kingdom

3

Subscribe